NeuroPace, Inc. (NASDAQ:NPCE) Stake Raised by Financial Advocates Investment Management

Financial Advocates Investment Management lifted its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 27.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,000 shares of the company’s stock after buying an additional 5,000 shares during the period. Financial Advocates Investment Management’s holdings in NeuroPace were worth $257,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NPCE. JPMorgan Chase & Co. boosted its position in NeuroPace by 106.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after acquiring an additional 6,181 shares during the period. Barclays PLC raised its stake in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares in the last quarter. State Street Corp lifted its holdings in NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the period. Geode Capital Management LLC grew its position in NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after buying an additional 25,330 shares in the last quarter. Finally, KCK LTD. bought a new stake in shares of NeuroPace during the 4th quarter worth about $58,981,000. 78.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NPCE has been the subject of several recent analyst reports. UBS Group started coverage on shares of NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price objective for the company. Wells Fargo & Company lifted their price target on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. upped their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and a consensus target price of $14.80.

Insider Transactions at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of NeuroPace stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now directly owns 87,062 shares in the company, valued at approximately $1,306,800.62. The trade was a 3.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.20% of the stock is currently owned by insiders.

NeuroPace Price Performance

NASDAQ NPCE opened at $13.12 on Monday. NeuroPace, Inc. has a 1 year low of $5.45 and a 1 year high of $18.15. The business’s fifty day moving average is $12.17 and its two-hundred day moving average is $9.08. The stock has a market capitalization of $391.63 million, a P/E ratio of -13.12 and a beta of 2.05. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same period in the prior year, the business posted ($0.28) earnings per share. On average, research analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.